These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30015676)

  • 1. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
    Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
    J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
    Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
    CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
    Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ
    CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R; Hard M; Weiden PJ
    Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal
    Hard ML; Wehr A; von Moltke L; Du Y; Farwick S; Walling DP; Sonnenberg J
    Ther Adv Psychopharmacol; 2019; 9():2045125319859964. PubMed ID: 31308935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole Lauroxil NanoCrystal
    Ehret MJ; Davis E; Luttrell SE; Clark C
    Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.
    Citrome L; Yagoda S; Bidollari I; Wang M
    J Clin Psychiatry; 2024 Feb; 85(1):. PubMed ID: 38416865
    [No Abstract]   [Full Text] [Related]  

  • 12. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
    Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole Lauroxil: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.